1.
Tran TH, Nguyen JV, Stecula A, Akutagawa J, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML. The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i&gt; and detectable in clinical samples prior to treatment. haematol [Internet]. 2021Aug.1 [cited 2024May28];106(8):2242-5. Available from: https://haematologica.org/article/view/haematol.2020.261354